Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder

Archives of Pediatrics and Adolescent Medicine

Volumn 160, Issue 1, 2006, Pages 82-90

  Wilens, Timothy E ^a   McBurnett, Keith ^b   Bukstein, Oscar ^e   McGough, James ^c   Greenhill, Laurence ^g   Lerner, Marc ^d   Stein, Mark A ⁱ   Conners, C Keith ^j   Duby, John ^l   Newcorn, Jeffrey ^h   Bailey, Charles E ⁿ   Kratochvil, Christopher J ^o   Coury, Daniel ^m   Casat, Charles ^k   Denisco, Mary Joan C ^f   Halstead, Patricia ^f   Bloom, Leslie ^f   Zimmerman, Brenda A ^f   Gu, Joan ^f   Cooper, Kimberly M ^f   Lynch, Joseph M ^f   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f McNeil Laboratories Inc   (United States)

^g NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k Behavioral Health Center   (United States)

^l AKRON CHILDREN'S HOSPITAL   (United States)

^m NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁿ CNS Healthcare Orlando Research Center   (United States)

^o NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ARTICLE; ASTHENIA; ATTENTION DEFICIT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; OSMOSIS; TREATMENT OUTCOME;

EID: 29944445386     PISSN: 10724710     EISSN: 10724710     Source Type: Journal    
DOI: 10.1001/archpedi.160.1.82     Document Type: Article

References (56)

1. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-1170.
2. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria, I: an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546-557.
3. Biederman J, Faraone SV, Taylor A, Sienna M, Williamson S, Fine C. Diagnostic continuity between child and adolescent ADHD: findings from a longitudinal clinical sample. J Am Acad Child Adolesc Psychiatry. 1998;37:305-313.
4. Hart EL, Lahey B, Loeber R, Applegate B, Frisk P. Developmental changes in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol. 1995;23:729-749.
5. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816-818.
6. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
7. Greenhill LL, Pliszka S, Dulcan MK, et al; American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(suppl):26S-49S.
8. Taylor E, Sergeant J, Doepfner M, et al; European Society for Child and Adolescent Psychiatry. Clinical guidelines for hyperkinetic disorder. Eur Child Adolesc Psychiatry. 1998;7:184-200.
9. Miller A, Lee S, Raina P, Klasen A, Zupanicic J, Olsen L. A Review of Therapies for Attention-Deficit/Hyperactivity Disorder. Ottawa, Ontario: Canadian Coordinating Office for Health Technology Assessments; 1998.
10. Lord J, Paisley S. The Clinical Effectiveness and Cost-effectiveness of Methylphenidate for Hyperactivity in Childhood. London, England: National Institute for Clinical Excellence; 2000.
11. National Institute for Clinical Excellence. Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention-Deficit/Hyperactivity Disorder (ADHD) in Childhood. London, England: National Institute for Clinical Excellence; 2000.
12. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? a meta-analysis. CMAJ. 2001;165:1475-1488.
13. Swanson JM, McBurnett K, Christian D, Wigal T. Stimulant medications in the treatment of children with ADHD. In: Ollendick TH, Prinz RJ, eds. Advances in Clinical Child Psychology. Vol 17. New York, NY: Plenum Press; 1995:265-322.
14. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2000;9:573-603 , viii.
15. Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextro-amphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 1991;36:141-155.
16. Smith BH, Waschbusch DA, Willoughby MT, Evans S. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/ hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev. 2000;3:243-267.
17. Stein MA, Baren M. Welcome progress in the diagnosis and treatment of ADHD in adolescence. Contemp Pediatr. 2003;20:83.
18. Swanson J, Lerner MA, Gupta S, Shoulson I, Wigal S. Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD. Arch Gen Psychiatry. 2003;60:204-211.
19. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. Available at: http://pediatrics.aapublications. org/cgi/content/full/107/6/e105. 2001;107:e105. Accessed November 28, 2005.
20. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:883-892.
21. Wilens T, Pelham W, Stein MA, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42:424-433.
22. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44:1015-1023.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
24. Ambrosini PJ. Historical development and present status of the schedule for affective disorders and schizophrenia for school-age children. J Am Acad Child Adolesc Psychiatry. 2000;39:49-58.
25. Shaffer D, Gould MS, Brasic J, et al. A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry. 1983;40:1228-1231.
26. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 2001;5:107-115.
27. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A doubleblind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434-443.
28. Spencer T, Biederman J, Wilens TE, Johnson M, Doyle R, Parekh S. Efficacy of MPH in adults with ADHD. Scientific poster presented at: 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 22-27, 2002; San Francisco, Calif.
29. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000;10:311-320.
30. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21:223-228.
31. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775-782.
32. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
33. DuPaul G, Power TJ, Anastopoulos AD, Reid D. ADHD Rating Scale-IV: Checklists, Norms and Clinical Interpretations. New York, NY: Guilford Press; 1998.
34. Bostic JQ, Biederman J, Spencer TJ, et al. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial. J Child Adolesc Psychopharmacol. 2000;10:205-216.
35. Prince JB, Wilens TE, Biederman J, et al. A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2000;10:193-204.
36. Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry. 1998;59(suppl 7):24-30.
37. Conners CK, Wells KC, Parker JD, Sitarenios G, Diamond JM, Powell JW. A new self-report scale for assessment of adolescent psychopathology: factor structure, reliability, validity, and diagnostic sensitivity. J Abnorm Child Psychol. 1997;25:487-497.
38. Frankel F, Weiner H. The Child Conflict Index: factor analysis, reliability, and validity for clinic-referred and nonreferred children. J Clin Psychol. 1990;19:239-248.
39. Stein MA, Blondis TA, Schnitzler ER, et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics. 1996;98:748-756.
40. National Institute of Mental Health. CGI (Clinical Global Impression) scale. Psychopharmacol Bull. 1985;21:839-843.
41. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:258-266.
42. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.
43. Evans SW, Pelham WE, Smith BH, et al. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol. 2001;9:163-175.
44. Lipsey MW, Wilson DB. The efficacy of psychological, educational, and behavioral treatment: confirmation from meta-analysis. Am Psychol. 1993;48:1181-1209.
45. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086.
46. Weiss M, Jain U. Clinical perspectives on the assessment of ADHD in adolescence. ADHD Rep. 2000;8:4-10.
47. Smith BH, Pelham WE Jr, Gnagy E, Molina B, Evans S. The reliability, validity, and unique contributions of self-report by adolescents receiving treatment for attention-deficit/hyperactivity disorder. J Consult Clin Psychol. 2000;68:489-499.
48. Schaughency E, McGee R, Raja SN, Feehan M, Silva PA. Self-reported inattention, impulsivity, and hyperactivity at ages 15 and 18 years in the general population. J Am Acad Child Adolesc Psychiatry. 1994;33:173-184.
49. Danckaerts M, Heptinstall E, Chadwick O, Taylor E. Self-report of attention deficit and hyperactivity disorder in adolescents. Psychopathology. 1999;32:81-92.
50. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002;5:189-202.
51. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86:184-192.
52. Greenhill LL, Osman BB. Ritalin: Theory and Practice. 2nd ed. Larchmont, NY: Mary Ann Liebert; 2000.
53. Klein RG, Bessler AW. Stimulant side effects in children. In: Kane JM, Lieberman JA, eds. Adverse Effects of Psychotropic Drugs. New York, NY: Guilford Press; 1992:470-496.
54. Anderson JC, Williams S, McGee R, Silva PA. DSM-III disorders in preadolescent children: prevalence in a large sample from the general population. Arch Gen Psychiatry. 1987;44:69-76.
55. Bird HR, Gould MS, Staghezza BM. Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry. 1993;32:361-368.
56. James A, Lai FH, Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand. 2004;110:408-415.